Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The innate immune response, clinical outcomes, and ex vivo HCV antiviral efficacy of a TLR7 agonist (PF-4878691).
Fidock MD, Souberbielle BE, Laxton C, Rawal J, Delpuech-Adams O, Corey TP, Colman P, Kumar V, Cheng JB, Wright K, Srinivasan S, Rana K, Craig C, Horscroft N, Perros M, Westby M, Webster R, van der Ryst E. Fidock MD, et al. Among authors: laxton c. Clin Pharmacol Ther. 2011 Jun;89(6):821-9. doi: 10.1038/clpt.2011.60. Epub 2011 Mar 30. Clin Pharmacol Ther. 2011. PMID: 21451504 Clinical Trial.
Design and optimisation of orally active TLR7 agonists for the treatment of hepatitis C virus infection.
Tran TD, Pryde DC, Jones P, Adam FM, Benson N, Bish G, Calo F, Ciaramella G, Dixon R, Duckworth J, Fox DN, Hay DA, Hitchin J, Horscroft N, Howard M, Gardner I, Jones HM, Laxton C, Parkinson T, Parsons G, Proctor K, Smith MC, Smith N, Thomas A. Tran TD, et al. Among authors: laxton c. Bioorg Med Chem Lett. 2011 Apr 15;21(8):2389-93. doi: 10.1016/j.bmcl.2011.02.092. Epub 2011 Mar 16. Bioorg Med Chem Lett. 2011. PMID: 21419626
Discovery of a highly potent series of TLR7 agonists.
Jones P, Pryde DC, Tran TD, Adam FM, Bish G, Calo F, Ciaramella G, Dixon R, Duckworth J, Fox DN, Hay DA, Hitchin J, Horscroft N, Howard M, Laxton C, Parkinson T, Parsons G, Proctor K, Smith MC, Smith N, Thomas A. Jones P, et al. Among authors: laxton c. Bioorg Med Chem Lett. 2011 Oct 1;21(19):5939-43. doi: 10.1016/j.bmcl.2011.07.076. Epub 2011 Aug 4. Bioorg Med Chem Lett. 2011. PMID: 21885277
Selection, optimization, and pharmacokinetic properties of a novel, potent antiviral locked nucleic acid-based antisense oligomer targeting hepatitis C virus internal ribosome entry site.
Laxton C, Brady K, Moschos S, Turnpenny P, Rawal J, Pryde DC, Sidders B, Corbau R, Pickford C, Murray EJ. Laxton C, et al. Antimicrob Agents Chemother. 2011 Jul;55(7):3105-14. doi: 10.1128/AAC.00222-11. Epub 2011 Apr 18. Antimicrob Agents Chemother. 2011. PMID: 21502629 Free PMC article.
Design, synthesis, and antiviral properties of 4'-substituted ribonucleosides as inhibitors of hepatitis C virus replication: the discovery of R1479.
Smith DB, Martin JA, Klumpp K, Baker SJ, Blomgren PA, Devos R, Granycome C, Hang J, Hobbs CJ, Jiang WR, Laxton C, Le Pogam S, Leveque V, Ma H, Maile G, Merrett JH, Pichota A, Sarma K, Smith M, Swallow S, Symons J, Vesey D, Najera I, Cammack N. Smith DB, et al. Among authors: laxton c. Bioorg Med Chem Lett. 2007 May 1;17(9):2570-6. doi: 10.1016/j.bmcl.2007.02.004. Epub 2007 Feb 4. Bioorg Med Chem Lett. 2007. PMID: 17317178
Use of qualitative integrative cycler PCR (qicPCR) to identify optimal therapeutic dosing time-points in a Respiratory Syncytial Virus Human Viral Challenge Model (hVCM).
Kelly G, Laxton C, Garelnabi M, Alton B, Addan F, Catchpole A, Thomas E, Borley D, Dee K, Boyers A, Bringas E, Noulin N, Lambkin-Williams R, Murray EJ. Kelly G, et al. Among authors: laxton c. J Virol Methods. 2015 Nov;224:83-90. doi: 10.1016/j.jviromet.2015.08.019. Epub 2015 Aug 31. J Virol Methods. 2015. PMID: 26335961
60 results